Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen

1. Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melano Moderna Investor Relations
2. AACR 2023 – more hope for Moderna’s neoantigen immunotherapy Evaluate Pharma
3. Pembrolizumab Plus Gemcitabine/Cisplatin Provided Significant Improvement in OS in Advanced Biliary Tract Cancer Pharmacy Times
4. Phase 2 Data of Personalized Cancer Vaccine With Adjuvant Pembrolizumab for Resected High-Risk Melanoma Dermatology Times
5. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial The Lancet
6. View Full Coverage on Google News

Read More: Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen